Version 1
: Received: 4 February 2024 / Approved: 5 February 2024 / Online: 5 February 2024 (15:09:27 CET)
How to cite:
Filippatos, F.; Tatsi, E.; Dourdouna, M.; Margeli, A.; Syriopoulou, V.; Michos, A. SARS-CoV-2 Seroepidemiology and Antibody Levels in Children during BA.5 Predominance Period. Preprints2024, 2024020288. https://doi.org/10.20944/preprints202402.0288.v1
Filippatos, F.; Tatsi, E.; Dourdouna, M.; Margeli, A.; Syriopoulou, V.; Michos, A. SARS-CoV-2 Seroepidemiology and Antibody Levels in Children during BA.5 Predominance Period. Preprints 2024, 2024020288. https://doi.org/10.20944/preprints202402.0288.v1
Filippatos, F.; Tatsi, E.; Dourdouna, M.; Margeli, A.; Syriopoulou, V.; Michos, A. SARS-CoV-2 Seroepidemiology and Antibody Levels in Children during BA.5 Predominance Period. Preprints2024, 2024020288. https://doi.org/10.20944/preprints202402.0288.v1
APA Style
Filippatos, F., Tatsi, E., Dourdouna, M., Margeli, A., Syriopoulou, V., & Michos, A. (2024). SARS-CoV-2 Seroepidemiology and Antibody Levels in Children during BA.5 Predominance Period. Preprints. https://doi.org/10.20944/preprints202402.0288.v1
Chicago/Turabian Style
Filippatos, F., Vasiliki Syriopoulou and Athanasios Michos. 2024 "SARS-CoV-2 Seroepidemiology and Antibody Levels in Children during BA.5 Predominance Period" Preprints. https://doi.org/10.20944/preprints202402.0288.v1
Abstract
This is a SARS-CoV-2 seroepidemiological study in pediatric population(0-16 years) during BA.5 Omicron predominance period in Athens metropolitan area. Serum samples were tested for SARS-CoV-2 nucleocapsid antibodies(Abs-N), representing natural infection during three sub-periods of BA.5 predominance: 01/05/2022-31/08/2022(period A), 01/09/2022-31/12/2022(period B) and July 2023(period C) and epidemiological data were collected. Additionally in period C Abs-N seronegative samples were tested for SARS-CoV-2 spike antibodies(Abs-S). A total of 878 children were tested (males:51.3%) with median age(IQR): 108(36-156) months and seropositivity during the 3 subperiods was: A:292/417(70%), B:288/356(80.9%), C:89/105(84.8%), P-value<0.001. SARS-CoV-2 seropositivity increased for from period A to C for 0-1-year (P-value: 0.044), 1-4 years (P-value: 0.028) and 6-12 years children (P-value: 0.003). Children 6-12y had the highest seroposi-tivity rates in all subperiods (A: 77.3%, B: 91.4% and C: 95.8%). A significant correlation of monthly SARS-CoV-2 median antibody titers with monthly seropositivity rates was detected (rs:0.812, P-value:0.008). During period C, an additional 12/105 (11.4%) Abs-S seropositive and Abs-N ser-onegative samples were detected and total seropositivity was estimated at 96.2% (101/105). The increased SARS-CoV-2 seropositivity detected in current seroepidemiology study illustrates a high exposure rate during BA.5 predominance period. These data could guide public health decisions regarding immunization strategies and protection measures.
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
